To understand and treat (environmental or pharmacological intervention) any disease we must first understand the physiologic and biochemical basis of that disease
The disease burden is growing with a steadily increasing morbidity, putting an enormous economical pressure on our (already overburdened) health care system
The Institute of Public Health in Ireland (IPH) forecasted from 2010-2020 a 50% increase in the number of people living with coronary heart disease and a 48% increase in strokes
The huge increase in the already heavy demand for our cardiovascular-related health services and a significant additional financial burden to our economy
The heart muscle becomes weak and is unable to supply sufficient blood flow to meet the needs of the body. Body tries to compensate by increasing heart rate.
Some cardiac muscle cells are self-excitable, meaning they contract without any signal from the nervous system
The sinoatrial (SA) node, or pacemaker, sets the rate and timing (rhythm) at which cardiac muscle cells contract
Impulses that travel during the cardiac cycle can be recorded as an electrocardiogram (ECG)
Cardiac dysrhythmia (or arrhythmia): group of conditions where there is abnormal electrical activity in the heart (too fast or too slow, and may be regular or irregular)
Abnormal awareness of the heart beat (palpitations) sometimes in rare cases indicate a life-threatening condition resulting in cardiac arrest (pacemaker/defibrillator)
Normal Haemostasis: a well-regulated process that maintains blood in a fluid, clot-free state in normal vessels and induces the rapid formation of a localised haemostatic plug at the site of vascular injury
Thrombosis: Pathological state of inappropriate activation of the normal haemostatic process within the non-interrupted vascular system, leading to thrombus (blood clots) formation that blocks blood flow to vital areas